Efficacy, safety and tolerability of rozanolixizumab in patients with chronic inflammatory demyelinating polyradiculoneuropathy: a randomised, subject-blind, investigator-blind, placebo-controlled, phase 2a trial and open-label extension study.
Fiche publication
Date publication
mai 2024
Journal
Journal of neurology, neurosurgery, and psychiatry
Auteurs
Membres identifiés du Cancéropôle Est :
Pr DE SEZE Jérôme
Tous les auteurs :
Querol L, De Sèze J, Dysgaard T, Levine T, Rao TH, Rivner M, Hartung HP, Kiessling P, Shimizu S, Marmol D, Bozorg A, Colson AO, Massow U, Eftimov F,
Lien Pubmed
Résumé
Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is a peripheral nerve disorder characterised by weakness and sensory loss. We assessed the neonatal Fc receptor inhibitor rozanolixizumab for CIDP management.
Mots clés
FC RECEPTOR, MOVEMENT DISORDERS, MYASTHENIA, NEUROMUSCULAR, RANDOMISED TRIALS
Référence
J Neurol Neurosurg Psychiatry. 2024 05 10;: